Effect of hyaluronic acid on vaginal atrophy in postmenopausal wome
- Conditions
- Vaginal atrophy.Senile (atrophic) vaginitis
- Registration Number
- IRCT2013022712644N1
- Lead Sponsor
- Vice chancellor for research Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 56
Major inclusion criteria: Married women past menopause who have symptoms?Non-Smoking? The use of drugs such as Heparin anticoagulants? Vaginal dryness and moderate to severe pain in the area during intercourse. (measured by visual criteria)? Do not use vaginal medications, hormonal and non-hormonal treatment for 30 days before? No history of known or suspected hormone-dependent diseases such as (breast cancer, cases of unexplained vaginal bleeding, acute Phlebitis or Thromboembolic disorders associated with estrogen and ...)
Major exclusion criteria: Need to cure vaginal infection in primary screening for Pap smear? Sensitivity (rash, erythema, inflammation, ...) to the drug or its ingredients? Lack of desire to continue working
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Maturity of vagina. Timepoint: Before and after eight weeks (end of intervention). Method of measurement: Calculate the percentage of cells in pap smear.;Vaginal PH. Timepoint: Before and after eight weeks (end of intervention). Method of measurement: By PH meter strips.
- Secondary Outcome Measures
Name Time Method Vaginal dryness. Timepoint: Before and after the intervention. Method of measurement: VAS.;Vaginal itching. Timepoint: Before and after the intervention. Method of measurement: VAS.;Urine incontinence. Timepoint: Before and after the intervention. Method of measurement: VAS.;Dyspareunia. Timepoint: Before and after the intervention. Method of measurement: VAS.